Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

876 Risultati di ricerca.

Nerventra Study Study drug dispensing and return

- 08/06/16 - 1 modulo, 3 itemgroups, 22 elementi, 1 linguaggio

Itemgroups: Demographic Information, Drug dispensed, Drug dispensing and return

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Baseline

- 07/06/16 - 1 modulo, 14 itemgroups, 111 elementi, 1 linguaggio

Itemgroups: Informed Consent and Demography Data, Safety measurements, Pasat Summary Score Sheet, 9-Hole Peg test, Binocular low contrast visual acuity, MRI Scan performance, MT Scan Performance, MRS Scan Performance, Modified Fatigue Impact Scale, General Health assessment, Final eligibility, Subject disposition, Post -Dose Vital signs, Phone thrombosis questionnaire

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Screening - Nerventra Study Sreening

- 06/06/16 - 1 modulo, 13 itemgroups, 192 elementi, 1 linguaggio

Itemgroups: Informed Consent and Demography Data, Multiple sclerosis history, Medical history, Safety measurements, Physical examination, FS,Ambulation,EDSS,AI, Timed 25-foot walk, Inclusion criteria, Exclusion criteria, Ancillary studies, Pharmacogenetic information, Subject disposition, Comments

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Unscheduled Visit

- 08/06/16 - 1 modulo, 4 itemgroups, 38 elementi, 1 linguaggio

Itemgroups: Demographic Information, Reason for unscheduled visit, Safety measurements, Exacerbation

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Laboratory data

- 08/06/16 - 1 modulo, 2 itemgroups, 12 elementi, 1 linguaggio

Itemgroups: Demographic Information, Laboratory parameter

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Medication log

- 08/06/16 - 1 modulo, 3 itemgroups, 19 elementi, 1 linguaggio

Itemgroups: Demographic Information, Medication log, Concomitant medications log

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 8

- 08/06/16 - 1 modulo, 2 itemgroups, 11 elementi, 1 linguaggio

Itemgroups: Informed Consent and Demography Data, Pasat Summary Score Sheet

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 10

- 08/06/16 - 1 modulo, 2 itemgroups, 25 elementi, 1 linguaggio

Itemgroups: Demographic Information, Safety measurements

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 5

- 08/06/16 - 1 modulo, 2 itemgroups, 16 elementi, 1 linguaggio

Itemgroups: Demographic Information, Safety measurements

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 3

- 08/06/16 - 1 modulo, 3 itemgroups, 22 elementi, 1 linguaggio

Itemgroups: Demographic Information, Frequent MRI Scan Performance, Repeated Frequent MRI Scan Performance

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 4

- 08/06/16 - 1 modulo, 2 itemgroups, 19 elementi, 1 linguaggio

Itemgroups: Demographic Information, 9-Hole Peg test

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Nerventra Study Visit 1

- 08/06/16 - 1 modulo, 3 itemgroups, 28 elementi, 1 linguaggio

Itemgroups: Demographic Information, Safety measurements, Population Pharmacokinetics

Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.